Investors
and Media

News Releases

Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Scientific and Standardization Committee Meeting

SOUTH SAN FRANCISCO, Calif. , July 06, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that data on betrixaban and andexanet alfa, as well as presentations on disease awareness and risk, would be presented at the International Society on Thrombosis and Haemostasis (ISTH) annual meeting, which is taking place from July 8-13 in Berlin, Germany.  

Details regarding the presentations follow.

Oral Presentation Details:

  • Presentation Title: Prevention of Exsanguination under Apixaban Anticoagulation Using Andexanet Alfa in a Polytrauma Model
  • Presenter: Oliver Grottke, M.D., Ph.D., RWTH University Hospital Aachen
  • Session Title: Bleeding Management Under Oral Anticoagulation
  • Presentation Date and Time: July 10, 2017 from 2:45-4:15 p.m. UTC
  • Session Room: London
     
  • Presentation Title: Prevalence of Major Medical Illnesses Associated with Venous Thromboembolism Risk in US Hospitals
  • Presenter: Alexander Cohen, MBBS, M.Sc., M.D., King’s College London
  • Session Title: DOACs and Beyond: Translational Aspects
  • Presentation Date and Time: July 13, 2017 from 9:30-10:45 a.m. UTC
  • Session Room: Berlin
     
  • Presentation Title: A Landmark Analysis of the APEX Study Comparing Extended Duration Betrixaban with Standard Duration Enoxaparin in Hospitalized Medically Ill Patients
  • Presenter: Alexander Cohen, MBBS, M.Sc., M.D., King’s College London
  • Session Title: Advances in Thromboprophylaxis
  • Presentation Date and Time: July 12, 2017 from 9:45-10:45 a.m. UTC
  • Location: Hall B
     
  • Presentation Title: Pharmacokinetic and Pharmacodynamic Modeling of Andexanet Alfa Dose to Reverse the Anticoagulant Activity of FXa Inhibitors in Patients with Acute Major Bleeding
  • Presenter: Janet Leeds, Ph.D., Portola Pharmaceuticals
  • Session Title: DOACs and Beyond: Translational Aspects
  • Presentation Date and Time: July 13, 2017 from 9:30-10:45 a.m. UTC
  • Session Room: Berlin
     

Poster Presentation Details:

  • Presentation Title: A Cross-Sectional, Multinational, Multidisciplinary Survey of Physicians Surrounding the Management of Bleeding Complications in the Setting of Direct Oral Anticoagulant Use
  • Presenter: Joseph Shaw, M.D., BSc, University of Ottawa
  • Poster Number: PB 472
  • Presentation Date and Time: July 10, 2017 from 12:00-1:15 p.m. UTC
  • Location: Exhibition Hall 2.2
     
  • Presentation Title: Impact of Evolving ACCP Guidelines on Estimates of Venous Thromboembolism Risk in US Hospitals
  • Presenter: Alexander Cohen, MBBS, M.Sc., M.D., King’s College London and Frederick Anderson, Jr., Ph.D., University of Massachusetts Medical School
  • Poster Number: PB 1193
  • Presentation Date and Time: July 11, 2017 from 12:00-1:15 p.m. UTC
  • Location: Exhibition Hall 4.2
     
  • Presentation Title: D-dimer in Acute Medically Ill Adults and Current Thromboprophylaxis: A Multicenter Observational Study Evaluating the Prevalence of Elevated D-dimer in Acute Medically Ill, Hospitalized Adults and Current Thromboprophylaxis Trends; the DAMIACT Study, Initial Data Analysis 
  • Presenter: Richey Neuman, M.D., M.P.H., F.A.C.P., Portola Pharmaceuticals
  • Poster Number: PB 1416
  • Presentation Date and Time: July 11, 2017 from 12:00-1:15 p.m. UTC
  • Location: Exhibition Hall 6.2

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.

 

 

Investor Contact:  
Mardi Dier  
Portola Pharmaceuticalsmdier@portola.com

Media Contact:
Julie NormartPure Communicationsjnormart@purecommunications.com
415.946.1087 

Primary Logo

Portola Pharmaceuticals, Inc.